ArticleScientific reports2026
Biogenic synthesis of gold nanoparticles using Coleus forskohlii leaf extract enhances anticancer activity against HT-29 cells and modulates the p53 regulated immune microenvironment in colon adenocarcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer remains a leading cause of cancer-related mortality worldwide, underscoring the urgent need for novel therapeutic strategies. In this study, we hypothesized that the synergistic combination of Coleus forskohlii leaf extract (CFLE) and its biogenically synthesized nanogold would enhance anticancer efficacy against HT-29 human colon adenocarcinoma cells by modulating reactive oxygen species (ROS) production and activating the tumor suppressor protein p53. Aqueous CFLE was prepared from dried leaves and used to synthesize gold nanoparticles, which were characterized by UV-Vis spectrophotometry, X-ray diffraction (XRD), and Fourier-transform infrared (FT-IR) spectroscopy. FT-IR analysis confirmed the presence of bioactive phytochemicals in CFLE capable of reducing and stabilizing the nanogold. Both CFLE and CFLE + nanogold demonstrated dose-dependent inhibition of HT-29 cell viability, accompanied by elevated ROS levels and significant upregulation of p53 expression. Combining of CFLE with the nanogold (extract + nanogold) could cancel the toxic effects of gold nanoparticles. Complementary bioinformatic analyses of colon adenocarcinoma datasets revealed that high TP53 expression correlates with improved patient survival and enhanced immune infiltration, particularly of B plasma cells, neutrophils, and M2 macrophages, mediated through chemokine signaling pathways. Our findings highlight the dual anticancer and antimicrobial potential of CFLE and CFLE + nanogold, with the nanocomposite formulation offering a novel, plant-based approach to colon cancer therapy through ROS-mediated p53 activation. In addition, CFLE could pause the toxic effects of the gold nanoparticles. This work positions TP53 not only as a central mechanistic node in CFLE + nanogold-induced cytotoxicity but also as a robust prognostic biomarker in colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.